

REMARKS

Election


In response to the Office Action of January 30 2002, applicants hereby elected the compound of Ex. 49., i.e., 6-[[1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy] hexanoic isopropyl ester. Applicants assume that further prosecution will be performed in accordance MPEP §809.02(c).

Amendments

The claims are amended to employ language in accordance with conventional U.S. practice and to delete superfluous language. New claims 25 and 26 are directed to the elected species.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "**Version with Markings to Show Changes Made**".

Respectfully submitted,



Brion P. Heaney (Reg. No. 32,542)
Attorney for Applicant(s)


MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
Direct Dial: (703) 812-5308
Facsimile No.: (703) 243-6410
Internet Address: heaney@mwzb.com

Filed: April 30, 2002

BPH/cas
K:\Sch\1738\Amend and Elect 3-15-02.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADE

--1. (Amended) A benzimidazole compound according to formula I



in which

R¹ means a monocyclic or bicyclic C₆₋₁₂ aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-4 heteroatoms selected from the group that consists of N, S or O, ~~whereby the mentioned~~ **wherein said aryl or heteroaryl group can be** **unsubstituted or is substituted with up to three of the following substituents, independently of one another:**

F, Cl, Br, I,

C(NH)NH₂, C(NH)NHR⁴, C(NH)NR⁴R^{4'}, C(NR⁴)NH₂, C(NR⁴)NHR^{4'},

C(NR⁴)NR⁴R^{4'},

XOH, XOR⁴, XOCOR⁴, XOCONHR⁴, XOCOOR⁴,

XCOR⁴, XC(NO⁴)R⁴, XC(NOR⁴)R^{4'}, XC(NO(COR⁴))R^{4'}

XCN, XCOOH, XCOOR⁴, XCONH₂, XCONR⁴R^{4'}, XCONHR⁴, XCONHOH,

XCONHOR⁴, XCOSR⁴

XSR⁴, XSOR⁴, XSO₂R⁴,

SO₂NH₂, SO₂NHR⁴, SO₂NR⁴R^{4'},

NO₂, XNH₂, XNHR⁴, XNR⁴R^{4'}, XNHSO₂R⁴, XN(SO₂R⁴)SO₂R^{4'},

XNR⁴SO₂R^{4'},

XNHCOR⁴, XNHCOOR⁴, XNHCONHR⁴, tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, **and R⁴**,

~~whereby two~~ **wherein two of said R¹ substituents at R¹**, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, ~~butane-1,4-diyl, or butane-1,4-~~ **diyl**;

R² means a monocyclic or bicyclic C₆₋₁₀ aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-4 heteroatoms selected from the group that consists of N, S or O, ~~whereby the mentioned~~ wherein said aryl or heteroaryl group ~~can be substituted~~ is unsubstituted or is substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, I,
XOH, XOR⁴, XOCOR⁴, XOCONHR⁴, XOCOOR⁴,
XCOR⁴, XC(NOH)R⁴, XC(NOR⁴)R^{4'}, XC(NO(COR⁴))R^{4'},
XCOOH, XCOOR⁴, XCONH₂, XCONHR⁴, XCONR⁴R^{4'}, XCONHOH,
XCONHOR⁴, XCOSR⁴,
XSR⁴, XSOR⁴, XSO₂R⁴, SO₂NH₂, SO₂NHR⁴, SO₂NR⁴R^{4'},
NO₂, XNHR⁴, XNR⁴R^{4'}, XNHSO₂R⁴, XN(SO₂R⁴)SO₂R^{4'}, XNR⁴SO₂R^{4'}, tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, and R⁴,

~~whereby two~~ wherein two of said R² substituents at ~~R²~~, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediyl-bisoxo, ethane-1,2-diylbisoxo, propane-1,3-diyl, ~~butane-1,4-diyl~~, or butane-1,4-diyl;

R³ means one or two ~~substituents, which form~~ substituents which are independently of one another:

hydrogen,
F, Cl, Br, I,
XOH, XOR⁴, XOCOR⁴, XOCONHR⁴, XOCOOR⁴,
XCOR⁴, XC(NOH)R⁴, XC(NOR⁴)R^{4'}, XC(NO(COR⁴))R^{4'},
XCN, XCOOH, XCOOR⁴, XCONH₂, XCONHR⁴, XCONR⁴R^{4'}, XCONHOH,
XCONHOR⁴, XCOSR⁴, XSR⁴, XSOR⁴, XSO₂R⁴, SO₂NH₂, SO₂NHR⁴,
SO₂NR⁴R^{4'},
NO₂, XNH₂, XNHR⁴, XNR⁴R^{4'},
XNHSO₂R⁴, XNR⁴SO₂R^{4'}, XN(SO₂R⁴)(SO₂R^{4'}),
XNHCOR⁴, XNHCOOR⁴, XNHCONHR⁴, tetrahydro-2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, or R³ ~~can be~~ R⁴,

~~whereby~~ wherein two substituents at R³, if they are in ortho-position to one another,

can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, ~~butane-1,4-diyl, or butane-1,4-diyl~~:

R^4 and $R^{4'}$, independently of one another, mean C_{1-4} perfluoroalkyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, (C_{1-3} alkyl- C_{3-7} cycloalkyl), C_{1-3} alkyl- C_{6-10} aryl, C_{1-3} alkyl-5 to 10-membered heteroaryl, with 1-4 N, S or O atoms, or C_{6-10} aryl or 5- to 10-membered heteroaryl with 1-4 N, S or O atoms, ~~whereby the~~ wherein aryl and heteroaryl groups ~~can be~~ are ~~unsubstituted or substituted with by one or two substituents from the group that consists of~~ selected from F, Cl, Br, CH_3 , C_2H_5 , NO_2 , OCH_3 , OC_2H_5 , CF_3 , ~~C_2F_5 or else and C_2F_5 , or~~ can carry an annelated methanediylbisoxy group or ethane-1,2-diylbisoxy group, and ~~in addition in~~ wherein a 5-membered cycloalkyl ring, can have an N or O ring member, and wherein ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, can have N and/or O, and wherein one or two ring members can be N and/or O, whereby which are each ring nitrogens optionally can be substituted with C_{1-3} alkyl or C_{1-3} alkanoyl,

R^5 and $R^{5'}$, independently of one another, mean C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, ~~whereby~~ wherein in each case a carbon atom can be exchanged for optionally replaced by O, S, SO, SO_2 , NH, N C_{1-3} alkyl or N C_{1-3} alkanoyl,

C_{3-7} cycloalkyl- C_{0-3} alkyl, ~~whereby in a 5-membered cycloalkyl ring, a~~ can optionally have an N or O ring member ~~can be an N or an O and in a 6- or 7-membered cycloalkyl ring, ring can optionally have one or two ring members can be~~ which are each N and/or O, ~~whereby~~ wherein ring nitrogens optionally can be substituted with C_{1-3} alkyl or C_{1-3} alkanoyl,

C_{6-10} aryl or 5- to 10-membered heteroaryl with 1-4 heteroatoms from N, S, and O, whereby the mentioned alkyl, alkenyl and alkynyl chains can be substituted with one of the previously mentioned cycloalkyls, aryls or heteroaryl,

whereby all previously mentioned alkyl and cycloalkyl radicals ~~with up to two substituents consisting of~~ can be substituted with up to two substituents selected from CF_3 , C_2F_5 , OH, O C_{1-3} alkyl, NH_2 , NH C_{1-3} alkyl, NH C_{1-3} alkanoyl, N (C_{1-3} alkyl) $_2$, N(C_{1-3} alkyl)(C_{1-3} alkanoyl), COOH, CONH $_2$, and COO C_{1-3} alkyl, and all previously mentioned aryl and heteroaryl groups can optionally be substituted with one or two substituents ~~from the group that consists of~~ selected from F, Cl, Br, CH_3 , C_2H_5 , NO_2 , OCH_3 , OC_2H_5 , CF_3 , ~~C_2F_5 and C_2F_5~~ , or else can carry an annelated methanediylbisoxy, ethane-1,2-diylbisoxy group,

or R^5 and $R^{5'}$ together with the nitrogen atom form a 5-to 7-membered heterocyclic

~~compound, group~~, which can optionally contain another oxygen, nitrogen or sulfur atom and can be optionally substituted ~~with~~by C₁₋₄ alkyl, C₁₋₄ alkoxy-C₀₋₂ alkyl, C₁₋₄ alkoxy-carbonyl, aminocarbonyl or phenyl,

A means C₁₋₁₀ alkanediyl, C₂₋₁₀ alkenediyl, C₂₋₁₀ alkinediyl, or (C₀₋₅ alkanediyl-C₃₋₇ cycloalkanediyl-C₀₋₅ alkanediyl), ~~whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in~~ can optionally have an N or O ring member, and a 6- or 7-membered cycloalkyl ring, can optionally have one or two ring members ~~can be~~ which are each N and/or O, whereby ring nitrogens optionally can be substituted with C₁₋₃ alkyl or C₁₋₃ alkanoyl,

whereby in ~~the~~ above-mentioned aliphatic chains, a carbon atom or two carbon atoms can be optionally replaced by ~~exchanged~~ for O, NH, N C₁₋₃ alkyl, N C₁₋₃ alkanoyl, and whereby alkyl or cycloalkyl groups can be optionally substituted with up to two substituents selected from ~~consisting of~~ =O, OH, O C₁₋₃ alkyl, NH₂, NH C₁₋₃ alkyl, NH C₁₋₃ alkanoyl, N (C₁₋₃ alkyl)₂, and N(C₁₋₃ alkyl)(C₁₋₃ alkanoyl),

B means COOH, COOR⁵, CONH₂, CONHNH₂, CONHR⁵, CONR⁵R⁵, CONHOH, CONHOR⁵,

SO₃H, SO₂NH₂, SO₂NHR⁵, SO₂NR⁵R⁵,

PO₃H, PO(OH)(OR⁵), PO(OR⁵)(OR⁵), PO(OH)(NHR⁵),

PO(NHR⁵)(NHR⁵), or

tetrazolyl,

in each case bonded to a carbon atom of group A,

or the entire group Y-A-B is N(SO₂R⁴)(SO₂R⁴) or NHSO₂R⁴,

X means a bond, CH₂, (CH₂)₂, CH(CH₃), (CH₂)₃, CH(CH₂CH₃),

CH(CH₃)CH₂, or CH₂CH(CH₃),

Y means O, NH, NR⁴, NCOR⁴, NSO₂R⁴,

provided that if Y means NH, NR⁴, NCOR⁴ or NSO₂R⁴, and

a) substituent R² contains a nitrogen-containing, saturated heterocyclic group ~~compound~~, this heterocyclic group ~~compound~~ is not substituted in the imine nitrogen with H, methyl, ethyl, propyl or isopropyl,

or

b) in optionally present groups XNHR⁴ or XNR⁴R⁴ of substituent R², R⁴ and/or

R⁴ does not mean C₁₋₄ alkyl,

that B does not mean COOH, SO₃H, PO₃H₂ or tetrazolyl at the same time, and R¹ and R², independently of one another, mean C₅₋₆ heteroaryl or phenyl, if the latter, independently of one another, are unsubstituted, or are substituted simply with C₁₋₆ alkyl, C₁₋₄ perfluoroalkyl, O C₁₋₆ alkyl, O C₁₋₄ perfluoroalkyl, COOH, COO C₁₋₆ alkyl, CO C₁₋₆ alkyl, CONH₂, CONHR⁴, NO₂, NH₂, NHCOR⁴, NHSO₂R⁴, or with 1 or 2 halogen atoms from the group that consists of F, Cl, Br, and I, and

whereby the following compounds are excluded:

[(1,2-Diphenyl-1H-benzimidazol-6-yl)oxy]acetic acid methyl ester,

5-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]pentanoic acid methyl ester,

4-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]butanoic acid ethyl ester,

5-[[1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-pentanoic acid methyl ester,

6-[[1-(4-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester,

5-[[1-(4-aminophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester,

5-[[1-[4-[[4-(chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester,

5-[[1-[4-[(acetyl)amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester

5-[[1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester,

6-[[1-(3-nitrophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester,

5-[[1-(3-aminophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester,

5-[[1-[3-[[4-(chlorophenyl)sulfonyl]amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester,


5-[[1-[3-[(acetyl)amino]phenyl]-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester.

13. (Amended) ~~Use of a compound according to claim 1 for the production of a A~~

process for preparing a pharmaceutical agent composition for treating or preventing diseases that are associated with a microglia activation comprising combining a compound according to claim 1 with a pharmaceutical vehicle or diluent.

14. (Amended) A pharmaceutical agent composition comprising one or more compounds according to claim 1 and one or more vehicles or diluents.

15. (Amended) Use of A method for treating a patient suffering from a disease associated with microglia activation comprising administering to said patient an effective amount of a benzimidazole compound of general formula II



in which

R¹ means a monocyclic or bicyclic C₆₋₁₂ aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-4 heteroatoms selected from ~~the~~ group that consists of N, S or and O, whereby ~~the mentioned~~ said aryl or heteroaryl group can be optionally substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, I, C(NH)NH₂, C(NH)NHR⁴, C(NH)NR⁴R^{4'}, C(NR⁴)NH₂,
 C(NR⁴)NHR⁴, C(NR⁴)NR⁴R^{4'}, XOH, XOR⁴, XOCOR⁴, XOCONHR⁴,
 XOCOOR⁴, XCOR⁴, XC(NOH)R⁴, XC(NOR⁴)R^{4'}, XC(NO(COR⁴))R^{4'}, XCN,
 XCOOH, XCOOR⁴, XCONH₂, XCONR⁴R^{4'}, XCONHR⁴, XCONHOH,

XCONHOR⁴, XCOSR⁴, XSR⁴, XSOR⁴, XSO₂R⁴, SO₂NH₂, SO₂NHR⁴, SO₂NR⁴R^{4'}, NO₂, XNH₂, XNHR⁴, XNR⁴R^{4'}, XNHSO₂R⁴, XN(SO₂R⁴)(SO₂R^{4'}), XNR⁴SO₂R^{4'}, XNHCOR⁴, XNHCOOR⁴, XNHCONHR⁴, tetrahydro-2,5-dioxopyrrol-1-yl, and 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, R⁴, ~~whereby~~ wherein two R¹ substituents at R¹, if they are in ortho-position to one another, can optionally be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, or butane-1,4-diyl;

R² means a monocyclic or bicyclic C₆₋₁₀ aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-4 heteroatoms selected from ~~the~~ group that consists of N, S ~~or~~ and O, ~~whereby the mentioned~~ wherein said aryl or heteroaryl group can be optionally substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, I, C(NH)NH₂, C(NH)NHR⁴, C(NH)NR⁴R^{4'}, C(NR⁴)NH₂, C(NR⁴)NHR^{4'}, C(NR⁴)NR⁴R^{4'}, XOH, XOR⁴, XOCOR⁴, XOCONHR⁴, XOCOOR⁴, XCOR⁴, XC(NOH)R⁴, XC(NOR⁴)R^{4'}, XC(NO(COR⁴))R^{4'}, XCN, XCOOH, XCOOR⁴, XCONH₂, XCONR⁴R^{4'}, XCONHR⁴, XCONHOH, XCONHOR⁴, XCOSR⁴, XSR⁴, XSOR⁴, XSO₂R⁴, SO₂NH₂, SO₂NHR⁴, SO₂NR⁴R^{4'}, NO₂, XNH₂, XNHR⁴, XNR⁴R^{4'}, XNHSO₂R⁴, XN(SO₂R⁴)(SO₂R^{4'}), XNR⁴SO₂R^{4'}, XNHCOR⁴, XNHCOOR⁴, XNHCONHR⁴, tetrahydro-2,5-dioxopyrrol-1-yl and, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-dioxoisindol-1-yl, R⁴, wherein ~~whereby~~ two R² substituents at ~~R²~~, if they are in ortho-position to one another, can be optionally linked to one another in such a way that they jointly form methanediyl-bisoxy, ethane-1,2-diylbisoxy,

propane-1,3-diyl, or butane-1,4-diyl;

R³ stands for one or two substituents, which ~~form~~ are each, independently of one another:

hydrogen, F, Cl, Br, I, XOH, XOR⁴, XOCOR⁴, XOCONHR⁴, XOCOOR⁴,
XCOR⁴, XC(NOH)R⁴, XC(NOR⁴)R⁴, XC(NO(COR⁴))R⁴,
XCN, XCOOH, XCOOR⁴, XCONH₂, XCONHR⁴, XCONR⁴R⁴, XCONHOH,
XCONHOR⁴, XCOSR⁴, XSR⁴, XSOR⁴, XSO₂R⁴, SO₂NH₂, SO₂NHR⁴,
SO₂NR⁴R⁴, NO₂, XNH₂, XNHR⁴, XNR⁴R⁴, XNHSO₂R⁴, XNR⁴SO₂R⁴,
XN(SO₂R⁴)(SO₂R⁴), XNHCOR⁴, XNHCOOR⁴, XNHCONHR⁴, tetrahydro-
2,5-dioxopyrrol-1-yl, 2,5-dihydro-2,5-dioxopyrrol-1-yl, 2,7-dihydro-2,7-
dioxoisindol-1-yl, or R⁴, ~~whereby~~ wherein two substituents **R³**, if they are in
ortho-position to one another, can be optionally linked to one another in such a
way that they jointly form methanediylbisoxo, ethane-1,2-diylbisoxo, propane-
1,3-diyl, or butane-1,4-diyl;

R⁴ and **R⁴**, independently of one another, mean C₁₋₄ perfluoroalkyl, C₁₋₆ alkyl, C₂₋₆
alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, (C₁₋₃ alkyl-C₃₋₇ cycloalkyl), C₁₋₃ alkyl-C₆₋₁₀
aryl, C₁₋₃ alkyl 5 to 10-membered heteroaryl, with 1-4 N, S or O atoms, C₆₋₁₀
aryl, or 5- to 10-membered heteroaryl with 1-4 N, S or O atoms,
~~whereby~~ wherein the C₆₋₁₀ aryl and heteroaryl groups can be optionally
substituted with one or two substituents selected from ~~the group that consists~~
~~of~~ F, Cl, Br, CH₃, C₂H₅, NO₂, OCH₃, OC₂H₅, CF₃, and C₂F₅, or else can carry
an annelated methanediylbisoxo group or ethane-1,2-diylbisoxo group, and ~~in~~
wherein a 5-membered cycloalkyl ring, ~~a ring member can be~~ optionally have
an N or O ring member, and ~~in~~ wherein a 6- or 7-membered cycloalkyl ring

cycloalkyl ring can optionally have one or two ring members ~~can be selected~~
from N and/or O, ~~whereby wherein~~ ring nitrogens optionally can be
substituted with C₁₋₃ alkyl or C₁₋₃ alkanoyl,

R⁵ and R^{5'}, independently of one another, mean hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆
alkinyl, ~~whereby wherein in each case~~ a carbon atom can be ~~exchanged~~
optionally replaced by O, S, SO, SO₂, NH, N C₁₋₃ alkyl or N C₁₋₃ alkanoyl,
C₃₋₇ cycloalkyl-C₀₋₃ alkyl, wherein ~~whereby in~~ a 5-membered cycloalkyl ring, ~~a~~
~~ring member can be~~ optionally have an N or an O ring member and in a 6- or
7-membered cycloalkyl ring can optionally have one or two ring members ~~can~~
~~be selected from~~ N and/or O, ~~whereby wherein~~ ring nitrogens optionally can be
substituted with C₁₋₃ alkyl or C₁₋₃ alkanoyl,
C₆₋₁₀ aryl or 5- to 10-membered heteroaryl with 1-4 heteroatoms selected from
N, S, and O, whereby the mentioned alkyl, alkenyl and alkinyl chains can be
substituted with one of the previously mentioned cycloalkyls, aryls or
heteroaryls,
whereby all previously mentioned alkyl and cycloalkyl radicals can optionally
be substituted with up to two substituents selected from ~~consisting of~~ CF₃,
C₂F₅, OH, O C₁₋₃ alkyl, NH₂, NH C₁₋₃ alkyl, NH C₁₋₃ alkanoyl, N (C₁₋₃ alkyl)₂,
N(C₁₋₃ alkyl)(C₁₋₃ alkanoyl), COOH, CONH₂, and COO C₁₋₃ alkyl, and all
previously mentioned aryl and heteroaryl groups can be optionally substituted
with one or two substituents selected from ~~the group that consists of~~ F, Cl, Br,
CH₃, C₂H₅, NO₂, OCH₃, OC₂H₅, CF₃, and C₂F₅, or else can carry an annelated
methanediylbisoxo, ethane-1,2-diylbisoxo group, or
R⁵ and R^{5'} together with the nitrogen atom form a 5-to 7-membered

heterocyclic ~~group compound~~, which can optionally contain another oxygen, nitrogen or sulfur atom and can be optionally substituted ~~with~~ by C₁₋₄ alkyl, C₁₋₄ alkoxy-C₀₋₂ alkyl, C₁₋₄ alkoxy-carbonyl, aminocarbonyl or phenyl,

A means C₁₋₁₀ alkanediyl, C₂₋₁₀ alkenediyl, C₂₋₁₀ alkinediyl, (C₀₋₅ alkanediyl-C₃₋₇ cycloalkanediyl-C₀₋₅ alkanediyl), (C₀₋₅ alkanediylarylene-C₀₋₅ alkanediyl), or (C₀₋₅ alkanediyl-heteroarylene-C₀₋₅ alkanediyl),

wherein ~~whereby~~ the aryl and heteroaryl groups can optionally be substituted with one or two substituents ~~that consist of~~ selected from F, Cl, Br, CH₃, C₂H₅, NO₂, OCH₃, OC₂H₅, CF₃, and C₂F₅, ~~whereby in wherein~~ a 5-membered cycloalkyl ring can optionally have a ring member ~~can be an~~ selected from N and O, and ~~in~~ a 6- or 7-membered cycloalkyl ring can optionally have one or two ring members ~~can be~~ selected from N and/or O, wherein ring nitrogens optionally can be substituted with C₁₋₃ alkyl or C₁₋₃ alkanoyl,

~~whereby wherein~~ the mentioned aliphatic chains, ~~a carbon atom~~ one or two carbon atoms can each optionally be exchanged for ~~replaced by~~ for O, NH, NR⁴, NCOR⁴, or NSO₂R⁴,

and wherein alkyl or cycloalkyl groups can be substituted with up to two substituents ~~consisting of~~ selected from F, OH, OR⁴, OCOR⁴, =O, NH₂, NR⁴R⁴, NHCOR⁴, NHCOOR⁴, NHCONHR⁴, NHSO₂R⁴ SH, and SR⁴,

B means hydrogen, OH, OCOR⁵, OCONHR⁵, OCOOR⁵, COR⁵, C(NOH)R⁵, C(NOR⁵)R⁵, C(NO(COR⁵))R⁵, COOH, COOR⁵, CONH₂, CONH₂NH₂, CONHR⁵, CONR⁵R⁵, CONHOH, CONHOR⁵, SO₃H, SO₂NH₂, SO₂NHR⁵, SO₂NR⁵R⁵,

or tetrazolyl, respectively bonded to a carbon atom of group A,

or the entire group **Y-A-B** is $N(SO_2R^4)(SO_2R^4)$ or $NHSO_2R^4$,

X means a bond, CH_2 , $(CH_2)_2$, $CH(CH_3)$, $(CH_2)_3$, $CH(CH_2CH_3)$, $CH(CH_3)CH_2$,
or $CH_2CH(CH_3)$,

Y means a bond, O, S, SO, SO_2 , NH, NR^4 , $NCOR^4$, NSO_2R^4 .

~~for the production of a pharmaceutical agent for treating or preventing diseases that are
associated with a microglia activation.~~

16. (Amended) ~~Use~~ A method according to claim 15, ~~whereby in general formula II~~
wherein

R¹ means a monocyclic or bicyclic aryl group or a monocyclic or bicyclic 5- to
10-membered heteroaryl group with 1-2 heteroatoms selected from ~~the group that consists of~~
N, S and ~~or~~ O, ~~whereby wherein said the mentioned~~ aryl or heteroaryl group can be optionally
substituted with up to three of the following substituents, independently of one another:

F, Cl, Br,

XOH, XOR^4 , $XOCOR^4$, $XOCONHR^4$, $XOCOOR^4$,

$XCOR^4$, XCN , $XCOOH$, $XCOOR^4$, $XCONH_2$, $XCONR^4R^4$, $XCONHR^4$,

$XCONHOH$,

$XCONHOR^4$, $XCOSR^4$, XSR^4 , NO_2 , $XNHR^4$, XNR^4R^4 , and

R^4 ,

~~whereby~~ wherein two **R¹** substituents at **R¹**, if they are in ortho-position to one
another, can be linked to one another in such a way that they jointly form methanediylbisoxo,
ethane-1,2-diylbisoxo, propane-1,3-diyl, butane-1,4-diyl.

17. (Amended) ~~Use~~ A method according to claim 15, ~~whereby in general formula~~
~~H,~~ wherein

R² means a monocyclic or bicyclic aryl group or a monocyclic or bicyclic 5- to
10-membered heteroaryl group with 1-2 heteroatoms selected from ~~the group~~
~~that consists of~~ N, S ~~or~~ and O, ~~whereby the mentioned~~ wherein said aryl group

10-membered heteroaryl group with 1-2 heteroatoms selected from ~~the group that consists of N, S or and O, whereby the mentioned wherein said~~ aryl group or heteroaryl group can be optionally substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, XOH, XOR⁴, XOCOR⁴, XOCONHR⁴, XOCOOR⁴,
 XCOR⁴, XC(NOH)R⁴,
 XC(NOR⁴)R^{4'}, XC(NO(COR⁴))R^{4'}, XCN, XCOOH, XCOOR⁴, XCONH₂,
 XCONR⁴R^{4'},
 XCONHR⁴, XCONHOH, XCONHOR⁴, XCOSR⁴, XSR⁴, XSOR⁴, XSO₂R⁴,
 SO₂NH₂, SO₂NHR⁴, SO₂NR⁴R^{4'}, NO₂, XNH₂, XNHR⁴, XNR⁴R^{4'}, XNHSO₂R⁴,
 XN(SO₂R⁴)(SO₂R^{4'}), XNR⁴SO₂R^{4'}, XNHCOR⁴, XNHCOOR⁴, XNHCONHR⁴,
 R⁴,

whereby two R² substituents, ~~at R²~~ if they are in ortho-position to one another, can be optionally linked to one another in such a way that they jointly form methanediylbisoxo, ethane-1,2-diylbisoxo, propane-1,3-diyl or, butane-1,4-diyl.

18. (Amended) Use A method according to claim 15, ~~wherein whereby in general~~
~~formula II~~

R³ stands for one or two substituents, which independently of one another, each mean:

hydrogen,

F, Cl, Br, XOH, XOR⁴, XOCOR⁴, XOCONHR⁴,
 XOCOOR⁴, XCOR⁴, XC(NOH)R⁴, XC(NOR⁴)R^{4'}, XC(NO(COR⁴))R^{4'},
 XCN, XSR⁴, XSOR⁴, XSO₂R⁴, SO₂NH₂, SO₂NHR⁴, SO₂NR⁴R^{4'}, NO₂, XNH₂,
 XNHR⁴, XNR⁴R^{4'}, XNHSO₂R⁴, XNR⁴SO₂R^{4'}, XN(SO₂R⁴)(SO₂R^{4'}),
 XNHCOR⁴, XNHCOOR⁴, XNHCONHR⁴, or R⁴, wherein ~~whereby~~ two
 substituents **R³**, if they are in ortho-position to one another, can be linked to
 one another in such a way that they jointly form methanediylbisoxo, ethane-
 1,2-diylbisoxo, propane-1,3-diyl or, butane-1,4-diyl.

R⁴ and **R^{4'}**, independently of one another, mean CF₃, C₂F₅, C₁₋₄

alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₆ cycloalkyl, (C₁₋₃ alkyl-C₃₋₆ cycloalkyl), C₁₋₃ alkylaryl, C₁₋₃ alkylheteroaryl, monocyclic aryl or 5- to 6-membered heteroaryl with 1-2 N, S or O atoms, wherein said whereby the aryl and heteroaryl groups can be optionally substituted with one or two substituents selected from ~~the group that consists of~~ F, Cl, Br, CH₃, C₂H₅, NO₂, OCH₃, OC₂H₅, CF₃ and, C₂F₅, or else can carry an annelated methanediylbisoxo or ethane-1,2-diylbisoxo group, and in addition ~~in~~ a 5-membered cycloalkyl ring can optionally have, a ring member ~~can be an~~ selected from N ~~or an~~ and O, ~~in~~ and a 6-membered cycloalkyl ring can optionally have, one or two ring members selected from ~~can be~~ N and/or O, ~~wherein whereby~~ ring nitrogens optionally can be substituted with C₁₋₃ alkyl or C₁₋₃ alkanoyl.

20. (Amended) Use A method according to claim 15, wherein whereby in general formula II

R⁵ and **R^{5'}**, independently of one another, can be C₁₋₆ alkyl, wherein

a carbon atom can optionally be ~~exchanged for~~ replaced by O, NH, N C₁₋₃ alkyl, N C₁₋₃ alkanoyl or, C₃₋₇ cycloalkyl-C₀₋₃ alkyl, ~~whereby in wherein~~ a 5-membered cycloalkyl ring; can optionally have a ring member ~~can be an~~ N ~~or~~ and an O, and ~~in~~ a 6- or 7-membered cycloalkyl ring; can optionally have one or two ring members ~~can be~~ selected from N and/or O, ~~whereby wherein~~ ring nitrogens optionally can be substituted with C₁₋₃ alkyl or C₁₋₃ alkanoyl, wherein whereby the mentioned C₁₋₆ alkyl part can optionally be substituted with one of the previously mentioned cycloalkyls or else a 5- to 6-membered heteroaromatic group compound with 1-2 heteroatoms, selected from ~~the group that consist of~~ N, S and ~~or~~ O, wherein whereby all previously mentioned alkyl and cycloalkyl parts can be substituted with up to two substituents selected from ~~that consists of~~ CF₃, OH, and O C₁₋₃ alkyl, and the previously mentioned heteroaryl groups can optionally be substituted with one or two substituents selected from ~~can consist of~~ F, Cl, CF₃, CH₃, C₂H₅, OCH₃ and, OC₂H₅,

or R⁵ and R^{5'} together with the nitrogen atom form a 5- to 7-membered heterocyclic ~~group compound~~ which optionally contains ~~can contain~~ another oxygen, nitrogen or sulfur atom and ~~can be~~ optionally substituted by with C₁₋₄ alkyl, C₁₋₄ alkoxy-C₀₋₂ alkyl, C₁₋₄ alkoxy-carbonyl, aminocarbonyl or phenyl.

21. (Amended) Use A method according to claim 15, ~~wherein~~ whereby in general formula II

A means C₁₋₁₀ alkanediyl, C₂₋₁₀ alkenediyl, C₂₋₁₀ alkinediyl, (C₀₋₅ alkanediyl-C₃₋₇ cycloalkanediyl-C₀₋₅ alkanediyl), or (C₀₋₅ alkanediyl-heteroaryl-C₀₋₅ alkanediyl), ~~wherein~~ whereby an optionally present ~~if a~~ heteroaryl group ~~can be~~ is present it is optionally substituted with one or two substituents ~~that consists of selected from~~ F, Cl, Br, CH₃, C₂H₅, NO₂, OCH₃, OC₂H₅, CF₃ and, C₂F₅, and in addition ~~in a~~ 5-membered cycloalkyl ring, can optionally have a ring member ~~can be an~~ selected from N ~~or an~~ and O, and ~~in a~~ 6- or 7-membered cycloalkyl ring can optionally have one or two ring members ~~can be selected from~~ N and/or O, ~~whereby~~ wherein ring nitrogens optionally can be substituted with C₁₋₃ alkyl or C₁₋₃ alkanoyl, wherein ~~whereby in an~~ aliphatic chains, ~~a carbon atom~~ one or two carbon atoms can be replaced by ~~exchanged for~~ O, NH, N C₁₋₃ alkyl, N C₁₋₃ alkanoyl, or NSO₂ C₁₋₃ alkyl, and whereby alkyl or cycloalkyl parts can be optionally substituted with up to two F atoms or ~~one of the~~ by the substituents selected from ~~that consists of~~ OH, O C₁₋₃ alkyl, O C₁₋₃ alkanoyl, =O, NH₂, NH C₁₋₃ alkyl, N (C₁₋₃ alkyl)₂, NH C₁₋₃ alkanoyl, N (C₁₋₃ alkyl) (C₁₋₃ alkanoyl), NHCOO C₁₋₃ alkyl, NHCONH C₁₋₃ alkyl, NHSO₂ C₁₋₃ alkyl, SH and, S C₁₋₃ alkyl.

22. (Amended) Use A method according to claim 15, ~~wherein~~ whereby in general formula II

B means hydrogen, OH, OCOR⁵, OCONHR⁵, OCOOR⁵, COOH, COOR⁵, CONH₂, CONHR⁵, CONR⁵R^{5'}, CONHOH, CONHOR⁵, or

tetrazolyl, in each case bonded to a carbon atom of group A.

23. (Amended) ~~Use~~ A method according to claim 15, ~~wherein~~ whereby in general formula II

X means a bond or CH₂.

24. (Amended) ~~Use~~ A method according to claim 15, ~~wherein~~ whereby in general formula II

Y means a bond, O, S, NH, NR⁴, NCOR⁴ or NSO₂R⁴